Ultisim Unveils New TalkEngine for AI-Driven Interactive Simulations at SparkNC Tech Creatives Summit
Harnessing generative AI and 3D simulation, TalkEngine is enabling a new generation of educational apps…
News
Kubecost Named to the Redpoint InfraRed 100 for Transformative Companies in Cloud Infrastructure
Kubecost Named to the Redpoint InfraRed 100 Kubecost is a comprehensive solution for monitoring, managing,…
Pre-Assembled Rugged Edge Networking Systems for Harsh Environments
EtherWAN’s rugged integrated networking enclosures, the EasyPoE® Series, gets a premier addition ANAHEIM, Calif., July…
FloQast and Crowe LLP Announce Strategic Alliance to Deliver Best-in-Class Accounting Workflow Automation
Collaboration empowers accounting teams with technology-driven transformation, improved communication, and enhanced efficiency LOS ANGELES, July…
AvePoint Announces Confidence Platform Updates to Enhance Digital Workplace Capabilities
New AvePoint Confidence Platform updates power digital transformation in the workplace, from data migration to…
Pawn Shop Map Announces App To Connect Customers With Pawn Shops Nearby
Miami, Florida–(Newsfile Corp. – July 25, 2023) – Today, Pawn Shop Map is announcing the…
CardioComm Solutions Responds to Cyber Security Incident
Toronto, Ontario–(Newsfile Corp. – July 25, 2023) – CardioComm Solutions, Inc. (TSXV: EKG) (“CardioComm” or…
Global Crypto Community Convenes at Dubai’s Blockchain Economy Summit, Uniting Industry Leaders for a Groundbreaking Event on October 4-5, 2023
DUBAI, Jul 25, 2023 – (ACN Newswire) – The Blockchain Economy Summit, recognized as the…
Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®
CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the…
Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®
CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the…
Adaptive Research Appoints Kristin Andruska, MD, PhD as Senior Medical Director and Clinical Neuroscience & Scientific Research Director
SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) — Adaptive Research, an organization committed to democratizing…
Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in…
Adaptive Research Appoints Kristin Andruska, MD, PhD as Senior Medical Director and Clinical Neuroscience & Scientific Research Director
SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) — Adaptive Research, an organization committed to democratizing…
Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in…
Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in…
Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in…
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
MIAMI, July 25, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the…
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
MIAMI, July 25, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the…
Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335
THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution…
Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335
THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution…